Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Blueprint Project update: how comparable are the results of different PD-L1 assays?
Adverse effects of immune checkpoint inhibitors
Immunotherapy: changing the landscape of cancer treatment
Avelumab and pembrolizumab for the treatment of merkel cell carcinoma
Sandra D'Angelo et al.